🚀Enjoy a 7-Day Free Trial Until Jul 20, 2024!

SG

Sigilon Therapeutics IncNASDAQ SGTX Stock Report

Price

Market cap $B

Exchange

XNAS - Nasdaq

FAIR VALUE

Is SGTX undervalued compared to its fair value?

The fair value of SGTX stock is hidden USD. Relative to the market price of 0 USD Sigilon Therapeutics Inc is hidden.

Sigilon Therapeutics, Inc. is a biopharmaceutical company, which engages in the research and development of therapeutic treatments for a wide range of chronic diseases. The company is headquartered in Cambridge, Massachu...[More about valuation]

Sigilon Therapeutics Fair Value

hidden
UNLOCK
What is fair value?

Market cap:

0.056 $B

Price:

Fair value:

hidden

Max value:

hidden

Min value:

hidden

P/E:

hidden

EPS:

-2.954

FINANCIALS

Sigilon Therapeutics financial for reporting period

Income Statement

0.0049 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.0072 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.0074 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
Revenue analysis

0.0049 B 100%
-0.0072 B -149%
-0.0074 B -152%

Balance Sheet

0.077 B
0.033 B

0.017 B

Financial Position Analysis

Assets

0.077 B
Current Assets
0.065 B
Total non-current assets
0.012 B

Total current liabilities
0.029 B
Total non-current liabilities
0.014 B

Cash Flow Statement

-0.013 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.011 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

Sigilon Therapeutics fundamental analysis for trailing twelve months (TTM)

Profitability score


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Solvency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Efficiency Indicators

-88 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%
-41 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Dupont Analysis

Stability Indicators

STOCK ANALYSIS

Is SGTX attractive for investment based on fundamental analysis?

SGTX stock rating is hidden. Sigilon Therapeutics is a hidden by Eyestock methodology.

Get SGTX Stock Rating
to complete you analysis
UNLOCK
Learn more about quality score?

Net Profit Margin:

-253

Gross Margin:

CFO / Debt ratio:

hidden

Current ratio:

2.518

Debt / Equity ratio:

0.452

ROE:

-88

ROIC:

hidden

Stability Ratio (2y):

hidden

Stability Ratio (5y):

hidden

Earnings quality:

hidden

SGTX analysis by AI

Eyebot AI analysis

We carefully consider 10 indicators for SGTX to calculate the final rating score. Use AI leverage to quickly get the main conclusions before diving into the details

Sigilon Therapeutics Inc competitors

AB

ABBV

Abbvie Inc

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Ill...

Discover

AM

AMGN

Amgen Inc

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company...

Discover

VR

VRTX

Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs fo...

Discover

Sigilon Therapeutics Inc dividends

SGTX dividend metrics

Payout ratio
Dividend yield
Annual dividend
Dividend streak
Average dividend yield over 3 years
Average dividend yield over 5 years

Dividend per share

By years
By payments
1y
3y
5y
All time
This ticker has no dividend history

About SGTX stock

About the company Sigilon Therapeutics Inc

Market cap $B

0.056

Dividend yield

Shares outstanding

32.46670000000001 B

Sigilon Therapeutics, Inc. is a biopharmaceutical company, which engages in the research and development of therapeutic treatments for a wide range of chronic diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 62 full-time employees. The company went IPO on 2020-12-04. The firm has developed its Shielded Living Therapeutics (SLTx platform), which is comprised of two primary elements: the cells and the sphere. The Company’s products candidate includes SIG-005, SIG-007, SIG-002 and SIG-001. SIG-005 is being developed to treat the non-neurological manifestations of mucopolysaccharidosis type 1 in patients with the disease. SIG-007 product is designed to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease. SIG-002 product is designed to replace islet cells for the treatment of Type 1 Diabetes. SIG-001 product candidate is designed to prevent bleeding episodes in patients with moderate to severe Hemophilia A.

SGTX profile

  • Ticker

    SGTX

  • Country

    USA

  • Exchange

    XNAS - Nasdaq

  • Report currency

    USD - US dollar

  • IPO date

    04 December 2020

  • Sector

    Healthсare

  • Industry

    Biotechnology

  • Employees

    62

  • City

    Cambridge

  • Address

    100 Binney Street, Ste 600

  • Cusip

    82657L107